| Public | Medicine retailer | Total |  |
---|---|---|---|---|
N = 466 | N = 1176 | N = 1642 | Â | |
% (95% CI) | % (95% CI) | % (95% CI) | P value | |
Patient reported consultation | ||||
Told HW about patient symptoms | 94.9 (94.4-95.4) | 44.3 (36.9-52.0) | 48.3 (41.3-55.4) | <0.001 |
Told HW that had a fever | 89.8 (87.2-91.9) | 40.3 (33.0-48.2) | 44.3 (37.1-51.4) | <0.001 |
HW asked follow up questions about patient's symptoms | 79.9 (76.3-83.0) | 32.0 (25.0-39.9) | 35.7 (29.1-43.1) | <0.001 |
Patient was physically examined | 65.1 (48.8-78.5) | 6.2 (3.5-10.5) | 10.8 (7.8-14.5) | <0.001 |
Patient had temperature taken | 49.7 (38.6-60.9) | 1.7 (0.6-4.9) | 5.5 (3.9-7.8) | <0.001 |
Patient tested for malaria at this facility | 5.8 (3.6-9.3) | 0.2 (0.0-1.4) | 0.7 (0.3-1.3) | <0.001 |
Patient requests for medicine | ||||
% of patients that asked for: | Â | Â | Â | Â |
   any type of medicine | 2.8 (1.9-4.2) | 65.4 (57.9-72.3) | 60.5 (53.7-66.9) | <0.001 |
   an anti-malarial | 1.2 (0.7-2.1) | 58.3 (51.1-65.2) | 53.8 (47.3-60.2) | <0.001 |
   any ACT | 0.9 (0.4-1.9) | 16.0 (11.1-22.5) | 14.8 (10.3-20.9) | <0.001 |
   Artemisinin monotherapy | 0 | 11.5 (8.6-15.3) | 10.6 (8.0-14.1) | 0.162 |
   Amodiaquine | 0 | 1.6 (0.8-3.4) | 1.5 (0.7-3.2) | 0.402 |
   Chloroquine | 0.1 (0.0-0.4) | 1.3 (0.6-2.7) | 1.2 (0.6-2.5) | <0.001 |
   Quinine | 0 | 0.7 (0.2-2.6) | 0.7 (0.2-2.4) | 0.631 |
   SP | 0.1 (0.1-0.1) | 26.2 (21.5-31.5) | 24.1 (19.8-29.1) | <0.001 |
Anti-malarial prescriptions | ||||
% patients prescription (from any facility) | 94.2 (92.4-95.6) | 15.4 (10.7-21.5) | 21.6 (17.1-26.9) | <0.001 |
% patients that received prescription from this facility | 94.2 (92.4-95.6) | 1.8 (0.7-4.0) | 8.8 (7.3-11.0) | <0.001 |
% patients that were prescribed*: | Â | - | - | - |
   an anti-malarial†| 78.4 (72.6-83.3) | - | - | - |
   any ACT‡ | 34.0 (21.9-48.7) | - | - | - |
   Artemisinin monotherapy | 4.7 (3.1-7.1) | - | - | - |
   Amodiaquine | 1.1 (0.9-1.5) | - | - | - |
   Chloroquine | 3.3 (0.8-11.6) | - | - | - |
   Quinine | 0.2 (0.0-3.1) | - | - | - |
   SP | 34.7 (21.7-50.6) | - | - | - |